Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL29161534 | 0.98 | ADORA2A (0.39) | ADORA2AADORA2B | |
| SCHEMBL20117306 | 0.78 | ADORA2A (0.47) | ADORA2AADORA2B | |
| SCHEMBL27259309 | 0.73 | ADORA2A (0.42) | ADORA2AADORA2B | |
| SCHEMBL17674371 | 0.73 | HSD17B10 (0.43) | ADORA2AADORA2B | |
| SCHEMBL30506328 | 0.73 | HSD17B10 (0.43) | ADORA2AADORA2B | |
| SCHEMBL17678134 | 0.73 | ADORA2A (0.39) | ADORA2AADORA2B | |
| SCHEMBL5134315 | 0.73 | PDE5A (0.35) | — | |
| SCHEMBL15345081 | 0.72 | ADORA2A (0.41) | ADORA2AADORA2B | |
| SCHEMBL2628318 | 0.72 | RPS6KA5 (0.32) | — | |
| SCHEMBL20116648 | 0.71 | ADORA2A (0.40) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116635029-A | REV-ERB agonists | 圣路易斯大学 | 2023-08-22 | — | — | CN | disclosed |
| WO-2022093552-A9 | REV-ERB AGONISTS | Saint Louis Univeristy (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1837329-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-26 | — | — | EP | disclosed |
| EP-1814885-A2 | NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006073610-A2 | NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| EP-0095289-B1 | IMIDAZO(1,2-C)PYRAZOLO(3,4-E)PYRIMIDINES AND THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286144-A1 | HETEROARYL DERIVATIVES | GPR119, SLC2A1, SLC2A4 | ADORA2A 405/4885ADORA2B 315/4885 |
| US-20080167306-A1 | Novel Heteroaryl Derivative | GPR119, SLC2A4, SLC5A2 | ADORA2A 678/4885ADORA2B 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.